Group items tagged

Folding Lightweight Wheelchairs For indoor wheelchair safety the folding power wheelchair models that are lightweight have front casters which turn easily, making them ideal for use in small apartments. Having the casters in front makes this a dangerous chair to use outdoors as the front wheels can turn sharply if encountering a crack in the sidewalk, incline, or rocks.Wheelchair india is manufacturer, supplier, distributor and dealer of Karma KP 10-2 Power Wheelchair for disabled and handicapped in india. They usually have one or two removable batteries and have a similar appearance as the manual wheelchair. They can be controlled with a joystick or a sip and puff method. Lightweight Power Assisted Wheelchairs These chairs can be propelled in a similar manner as the manual wheelchair or use a battery. You may want this type if you want to keep fit and get some exercise but need some power when going up an incline or when traveling a distance. They are smaller and lighter weight than the folding wheelchair and have smaller batteries and motors. Dual Purpose Power Wheelchairs These chairs generally are good for either indoor or outdoor use. You need to have larger wheels in front for outdoors as this is a safety feature. It is better to have six wheels for stability when traveling outdoors. These indoor/outdoor power chairs compromise wheelchair safety and perform poorly when you do not have enough room to turn indoors and you need to travel over rough ground and uneven surfaces. Their optimum performance indoors is when you have wider doors and hallways in assisted living facilities, nursing homes, or homes/apartments. Ideal outdoor surfaces in urban and suburban areas would include sidewalks and paved areas. Outdoor Power Wheelchairs These chairs weigh as much as 400-500 pounds, add the weight of the user up to 250 pounds and the total weight is approximately 650 pounds. They are very efficient outdoors with their rear wheels they can sa

A groundbreaking study analysing data from nearly 600,000 cancer patients in England has shed light on the increased risk of second cancers among breast cancer survivors. The research conducted by University of Cambridge in association with the Lancet Regional Health-Europe studied data from over 580,000 female and over 3,500 male breast cancer survivors diagnosed between 1995 and 2019 using the National Cancer Registration Dataset. The findings suggest that survivors of breast cancer, the most prevalent cancer in the UK, face a substantially higher risk of developing second primary cancers. According to the research, female survivors exhibited a twofold increase in the risk of contralateral breast cancer compared to the general population. The data highlighted an 87 per cent greater risk of endometrial cancer, a 58 per cent greater risk of myeloid leukemia, and a 25 per cent greater risk of ovarian cancer in female survivors.

A surrogate mother often faces criticism and judgment from others for the choice she have made. However, those are less problematic when compare to the risks that she takes for her own family, friends and spouse. These risks can be daunting and cause challenges she might not have considered before getting involved. These risks can be anything from medical and health concerns to finances and job security and often family and personal risks as well. Medical risk is a huge factor, when a woman becomes a surrogate often times, she and the donors would have to undergo intense examination. These exams range from blood, health tests to the initial process of the implanting of the eggs from the donor. In the beginning the clinic will bring her and the egg donor together to begin a lengthy process of sequencing ovulation cycles. The clinic would put the surrogate mother on birth control and steroids, such as Luprin. These medications are meant to get both the surrogate mother and the donor's cycles on the same schedule. This is crucial because the surrogates' uterus needs to be ready for the embryos. Just having to deal with the pain of insemination and testing can be unbearable, not to mention the unpleasant side effects from all the medication and actual insemination process. However, that is just part of it. The surrogates are also faced with depression, sleep disturbance, guilt and the difficulty to remain unattached. These factors alone cause many surrogates to face the fact that they are walking a long road that not many others might have the strength to do. Many clinics offer support groups and counseling. Aside from medical and emotional risks, there might also be legality issues with the laws of the state they reside in. What kind of laws protect the surrogate, what rights does she have to things such as privacy? And there are also finances to consider. Generally, surrogate mothers are responsible for all insurance costs. As a surrogate you should be financially

A comprehensive cohort study has shed light on the benefits and risks associated with weight-loss drugs, offering valuable insights for clinical care and future research. Published in Nature Medicine on 20 January 2024, the study found the use of glucagon-like peptide 1 receptor agonists (GLP-1RAs)-used to treat diabetes and obesity-associated with a reduced risk of substance use disorders (including alcohol, cannabis, opioid and stimulant use disorders). Weight-loss drug use was also linked to decreased risks of psychotic disorders, seizures, neurocognitive disorders (including Alzheimer's disease and dementia), coagulation disorders, cardiometabolic disorders, infectious illnesses and several respiratory conditions. However, the use of GLP-1RAs was not without risks, as researchers identified an increased risk of gastrointestinal disorders, hypotension, syncope, arthritic conditions, nephrolithiasis, interstitial nephritis, and drug-induced pancreatitis associated with their use. The analysis, utilising the U.S. Department of Veterans Affairs databases, compared 215,970 GLP-1 RA users with patients using sulphonylureas (n=159,465), DPP4 inhibitors (n=117,989), SGLT2 inhibitors (n=258,614), or a composite of the three (n=536,068).

Following the publication of a new study by the British Medical Journal (BMJ) that estimates the economic impact and prevelance of hazardous NSAID prescribing in England, the Royal Pharmaceutical Society (RPS) has underscored the pressing need for enhanced safety measures in medication management. The study, led by RPS Fellow Rachel Elliott, reveals significant health and financial costs associated with the high-risk prescribing of oral non-steroidal anti-inflammatory drugs (NSAIDs) among vulnerable populations. James Davies, Director for England at the RPS, emphasised the critical findings of the research. "Improving the safety of NSAID prescribing requires a multi-pronged approach, that educates and supports prescribers on the risk, as well as uses the skills of pharmacists in the primary care team to help identify higher risk patients and prescribing scenarios," Davies remarked. The study highlights that NSAIDs, while effective in managing pain and inflammation, are associated with serious adverse events, including gastrointestinal bleeding, renal dysfunction, and cardiovascular issues.

The Johnson & Johnson drug Darzalex showed promise in helping keep a precancerous condition from progressing to the blood cancer multiple myeloma for those at high risk, according to results from a trial presented at the American Society of Hematology meeting in San Diego. Darzalex, a monoclonal antibody that targets a protein found on the surface of myeloma cells known as CD38, significantly reduced patients' risk of developing the blood cancer and improved their survival in an international late-stage trial. "These results are a major advancement in the treatment of high-risk smoldering multiple myeloma," study leader Dr. S. Vincent Rajkumar of the Mayo Clinic Comprehensive Cancer Center in Rochester, Minnesota said in a statement. In smoldering multiple myeloma, abnormal plasma cells accumulate in the bone marrow. As the abnormal cells and certain proteins accumulate, a patient's risk for cancer increases.

Getting a good night's sleep is crucial for maintaining both physical and mental health, alongside a balanced diet and regular exercise. Chronic sleep deprivation has been linked to an increased risk of serious conditions like diabetes and heart disease. So, if you're sleep deprived during weekdays, try to make up for it by getting extra sleep on weekends. A new study has revealed catching up with compensatory sleep on weekends can significantly reduce the risk of heart disease. The study conducted by the National Centre for Cardiovascular Disease in Beijing, China, found that individuals who catch up on sleep over the weekend may lower their risk of heart disease by one-fifth. Study co-author Yanjun Song from the State Key Laboratory of Infectious Disease at Fuwai Hospital emphasised that the benefit of compensatory sleep was even more pronounced among individuals who regularly experience inadequate sleep on weekdays. The researchers used data from 90,903 subjects involved in the UK Biobank project to evaluate the relationship between compensated weekend sleep and heart disease. More than 21 per cent of the participants were identified as sleep-deprived - defined as getting less than seven hours of sleep per night.

The European Medicines Agency's (EMA) Pharmacovigilance Risk Assessment Committee (PRAC) has initiated a review of semaglutide-containing medicines after concerns were raised regarding a potential increased risk of non-arteritic anterior ischemic optic neuropathy (NAION), a rare eye condition. Semaglutide, a glucagon-like peptide 1 receptor agonist (GLP-1 RA), is used in the treatment of diabetes and obesity, with medicines like Ozempic, Rybelsus, and Wegovy containing the active substance. A report from the PRAC highlighted two recent observational studies that suggest patients treated with semaglutide may face a higher risk of developing NAION. This condition, caused by reduced blood flow to the optic nerve, can result in vision loss in the affected eye. However, two other recent observational studies did not show an increased risk, according to the report.

Use of cholesterol lowering drugs may significantly cut cardiovascular risks, but its long term use can raise the risk of developing cataracts by 27 percent, researchers have found.

Surrogacy is perhaps one of the most selfless acts that a woman can bestow upon a couple in need of a child. Surrogacy, however, can come with both physical and physiological risks that may or may not be easy to recover from. Understanding what the psychological risks of surrogate motherhood can make the transition from carrying a child to relinquishing that child easier. The psychological risks of surrogate motherhood may be a heavier burden to carry, but pre-screening and on-going counseling both before and after the event can help surrogate mothers adjust. There are four areas that are of particular interest in the psychological aspect of surrogacy: contact (bonds), control, closure and ethics. Surrogate mothers form relationships with the couples they surrogate for and that bond may perhaps be even stronger than the bond they may feel for the child they are carrying. They see and talk to their couples regularly and become used to the caring bestowed upon them from their couples. These bonds are strengthened by the routine prenatal visits, maternity clothes shopping, calls to see how they are feeling or if they need anything for comfort. These routine events cause them to become almost dependent on their couples and some surrogates report even becoming depressed after the birth not because of having to relinquish the child, but because they no longer have a reason for contact with their couples. Another one of the psychological risks of surrogate motherhood is that of closure. Often, this can go hand in hand with every contact or bonding issues. The routines and relationships developed between the surrogate, couples and medical staff that often make the transition from pregnancy and surrogacy to the birth and farewell stage that makes it difficult. Not only does the surrogate have to deal with the loss of a child, per se, but also the loss of those unique and caring relationships and routines that they have grown used to over the previous nine months. And fina

A woman must fully comprehend what it means to be a surrogate mother. She needs to know what her body will go through, what the couple she is working for will expect of her while she is carrying their child and what the risks are in all of this. A woman may enjoy the idea of being pregnant and carrying a child but she must think of the risks of surrogate motherhood before she embarks on such a long journey. One of the risks involved in surrogate motherhood is the pregnancy itself. A natural pregnancy is dangerous; let alone an artificial one. Complications happen that can't always be avoided. It is simple fate that may lead you to miscarry, or acquire health problems from the pregnancy. Though using a surrogate motherhood agency is the safest way to go, no one can promise you that there will be no complications. If and when you are pregnant with someone else's child, you are responsible for taking care of it while in your womb. What you eat, drink and take into your body will affect the child. Not everyone has the self discipline to take their vitamins every day or not smoke a cigarette. If something happens and the child is born with a problem that could possibly be because of you and what you did to your body during pregnancy, then you will be investigated. It may not have been your fault, but if the possibility exists then the agency has to look into it. When you get into surrogate motherhood, you become business partners with the parents of the child for the duration of the pregnancy. There is no backing out. If the couple that you chose turns out to be mean or irresponsible, you are stuck with them until the baby is born. This is especially dangerous if you are not using a surrogate agency. If the couple skips town, you won't be taken care of and will be stuck with a baby to raise. What happens if the child is born with some kind of deformity or disease? The parents may not want the child. So then, is it you that takes care of it? Is it put up for a

New research shows that lifelong excess weight almost doubles a woman's risk of developing womb cancer. The findings of the study were published in 'BMC Medicine'. The study from the University of Bristol is one of the first to find that for every fiver extra BMI units, a woman's risk of womb (endometrial) cancer is almost doubled (an increase of 88 per cent). This is higher than most previous studies have suggested and reflects lifelong weight status rather than a snapshot in time like most other studies. Five BMI units is the difference between the overweight category and the obese category, or of a 5'5 adult woman being two stones heavier. The international study looked at genetic samples from around 120,000 women from Australia, Belgium, Germany, Poland, Sweden, the UK, and the USA of which around 13,000 had womb cancer. This large statistical analysis is one of the first studies of its kind to look at the effect of lifelong greater BMI on womb cancer risk.

The Joint Committee on Vaccination and Immunisation (JCVI) has advised booster vaccination to be offered this autumn (2023) for those at higher risk of severe Covid-19 in its interim advice to government on the coronavirus (COVID-19) vaccination programme for 2023. The JCVI also advised that for a smaller group of people, such as those who are older and those who are immunosuppressed, an extra booster vaccine dose in the spring should also be planned for. Professor Wei Shen Lim, Chair of Covid-19 vaccination on the JCVI, said: "The Covid-19 vaccination programme continues to reduce severe disease across the population, while helping to protect the NHS. That is why we have advised planning for further booster vaccines for persons at higher risk of serious illness through an autumn booster programme later this year. We will very shortly also provide final advice on a spring booster programme for those at greatest risk."

The widely-held concept that levels of "good" cholesterol in the blood can indicate heart disease risk is not equally true for Blacks and whites, and the measure itself may be of less value than previously thought, according to a U.S. study published on Monday (November 21). Various types of cholesterol are thought to have either healthy or unhealthy effects. Low levels of so-called "good" high-density lipoprotein (HDL) cholesterol were linked with higher odds for developing cardiac problems in the long-term study - but only in white participants, the study published in the Journal of the American College of Cardiology found. In contradiction to what has generally been assumed, low HDL levels did not confer any higher risk of heart disease in Black people, researchers said. Among white people, however, those with HDL levels below 40 milligrams per deciliter had a 22% higher risk for coronary heart disease compared with those whose HDL levels were higher. High HDL levels (above 60 mg/dL), which are thought to be protective, were not linked with lower coronary heart disease risks in either race, researchers found.

The World Health Organization said on Sunday (May 29) that monkey pox constitutes a "moderate risk" to overall public health at global level after cases were reported in countries where the disease is not typically found. "The public health risk could become high if this virus exploits the opportunity to establish itself as a human pathogen and spreads to groups at higher risk of severe disease such as young children and immunosuppressed persons," WHO said. As of May 26, a total of 257 confirmed cases and 120 suspected cases have been reported from 23 member states that are not endemic for the virus, the health agency said in a statement. There has been no reported fatalities so far. WHO also said that the sudden appearance of monkeypox at once in several non-endemic countries suggests undetected transmission for some time and recent amplifying events. The agency added that it expects more cases to be reported as surveillance in endemic and non-endemic countries expands. Monkeypox is an infectious disease that is usually mild, and is endemic in parts of west and central Africa. It is spread by close contact, so it can be relatively easily contained through measures such as self-isolation and hygiene.

Recently launched generic version of Apixaban by Teva UK is said to bring savings to the NHS drug bill while making sure patients get the medicine they need. The generic apixaban is available for the prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (NVAF), with one or more risk factors, such as prior stroke or transient ischaemic attack (TIA) and treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults. Previously there was only a 'branded' product available, but Castleford-based Teva UK succeeded in invalidating the apixaban patent and SPC (supplementary protection certificate) in the UK High Court and so is now able to launch its own 'generic' version - which will bring savings for the NHS while making sure patients get the medicine they need. "We've always said that we stand up for the patient", said Kim Innes, General Manager of Teva UK and Ireland. "The launch of generic apixaban emphasises Teva's commitment to doing the right thing by putting patients at the heart of everything we do by giving them and the NHS access to affordable treatments." Apixaban is an anticoagulant which directly inhibits factor X (factor Xa), inhibiting thrombin formation and the development of thrombi (blood clots). For at-risk patients, such as those with, or at risk for DVT, or NVAF, the risk of stroke related to blood clots forming in the body and traveling to the brain is a serious concern. Each year, DVT affects around 1 person in every 1,000 in the UK and if left untreated, about 1 in 10 people with a DVT will develop a PE.

UK regulator has approved a second oral antiviral for early treatment of Covid-19 in high-risk adults, after molnupiravir. The Medicines and Healthcare products Regulatory Agency (MHRA) gave its nod for a new treatment called Paxlovid (PF-07321332 and ritonavir), after finding it safe and effective at reducing the risk of hospitalisation and death in people diagnosed with mild Covid-19 infection. Developed by Pfizer, Paxlovid prevents the multiplying of virus, helping the body to overcome the infection. A clinical trial for the treatment in high risk individuals revealed that a five-days course of Paxlovid reduces the risk of hospitalisation and death by 89 per cent. It further revealed that Paxlovid is most effective when taken in the early stage of infection. Dr June Raine, MHRA chief executive, said: "We now have a further antiviral medicine for the treatment of Covid-19 that can be taken by mouth rather than administered intravenously. This means it can be administered outside a hospital setting, before Covid-19 has progressed to a severe stage."